Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ORION B

ORNBV.HEFI0009014377NASDAQ HelsinkiFIEUR
Stock price
ORION B
Loading chart...

Coverage

Latest articles

U.S. FDA approves new indication for Orion-Bayer prostate cancer drug
8 Jun 2025, 20:27ORNBV.HENASDAQ Helsinki

Filings

Recent filings

FilingDate
Decisions by the AGM of Orion Corporation held on 21 March 200622 Mar 2006
Vice Chairman and Committees of the Board of Directors of Orion Corporation22 Mar 2006
CEO Jukka Viinanen at Orion?s AGM today: Good start for the year in Orion Pharma21 Mar 2006
Orion appoints Pellervo Hämäläinen VP, Communications and IR, for future Oriola-KD20 Mar 2006
Enquiry concerning pharmacy agreements of Orion and Oriola removed from handling of Comp. A20 Mar 2006
Board of Directors of Kronans Droghandel7 Mar 2006
Orion Group Annual Report 2005 published1 Mar 2006
Orion Group 2005 Financial Statements
Search

Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).

  • Previous
  • 1
  • 2
  • Next
9 Feb 2006
Matters to be handled at Orion?s AGM on 21 March 20069 Feb 2006
Recommendation by the nomination committee concerning Boards of Directors to be elected by the AGM30 Jan 2006
Orion appoints Kimmo Virtanen CFO of the Wholesale and Distribution Division27 Jan 2006
Orion updates information about Abbott's progress with Simdax26 Jan 2006
  • Previous
  • 1
  • More pages
  • 83
  • 84
  • 85
  • More pages
  • 95
  • Next
Company
ORION B
ORNBV.HENASDAQ Helsinki
Website: Unavailable
Coverage
7
Filings
1,130